[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
Conditions such as hypothyroidism, obstructive sleep apnoea, and hormonal changes associated with perimenopause may also affect hunger levels
Tirzepatides dual-action mechanism, targeting both GLP-1 and GIP receptors, offers broader metabolic benefits, which may contribute to greater and more sustained weight loss compared to Semaglutide GLP-1, which primarily targets GLP-1 receptors
What Is Dry Mouth
PlexusDx believes in transparent, predictable pricing: your dose may need to go up, but your price won't
Our medical weight loss programs utilize prescription medications to support you in shedding excess weight and keeping it off long-term
